Iridex Board Member Beverly Huss Receives Major Stock Incentive Package

Rhea-AI Filing Summary

This Form 4/A filing amends a previously filed Form 4 dated June 17, 2025, reporting insider trading activity for Beverly A. Huss, a Director of Iridex Corp (IRIX). The amendment discloses a stock option grant that occurred on June 13, 2025.

Key details of the transaction:

• Granted 53,000 stock options to purchase common stock
• Exercise price set at $0.94 per share
• Options expire on June 13, 2032
• Vesting occurs at earlier of one-year anniversary or 2026 annual stockholder meeting

The stock options were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. The filing was signed by Nilo De Castro as attorney-in-fact for Beverly Huss on June 24, 2025.

Positive

• Director Beverly Huss granted 53,000 stock options at $0.94 per share, aligning long-term interests with shareholders through significant equity compensation

Negative

• None.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUSS BEVERLY A

(Last) (First) (Middle)

1212 TERRA BELLA AVENUE

(Street)

MOUNTAIN VIEW CA 94043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/17/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock (right to buy)(1)	$0.94	06/13/2025		A		53,000		(2)	06/13/2032	Common Stock	53,000	$0	53,000	D

Explanation of Responses:

1. This option was granted pursuant to the Company's 2008 Equity Incentive Plan, as amended, and is exempt pursuant to Rule16b-3.

2. All shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the Company's 2026 annual meeting of stockholders.

	/s/ Nilo De Castro, Attorney-in-fact for Beverly Huss	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did Beverly Huss receive from IRIX on June 13, 2025?

Beverly Huss received 53,000 stock options to buy IRIX common stock at an exercise price of $0.94 per share. These options were granted under the Company's 2008 Equity Incentive Plan and will expire on June 13, 2032.

When do Beverly Huss's IRIX stock options vest?

The stock options will vest and become exercisable upon the earlier of: (1) the one-year anniversary of the grant date (June 13, 2026) or (2) IRIX's 2026 annual meeting of stockholders.

Why did IRIX file an amended Form 4 (Form 4/A) for Beverly Huss?

The Form 4/A was filed as an amendment to the original Form 4 that was filed on June 17, 2025. This amended filing was made to correct or update information from the original filing regarding Beverly Huss's stock option grant.

What is Beverly Huss's role at IRIX?

According to the filing, Beverly Huss serves as a Director on IRIX's Board of Directors. This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.